ALLEGORY: Obinutuzumab Demonstrates Superiority Over Placebo Across All Key End Points in SLE

Roche's obinutuzumab (Gazyva/Gazyvaro) significantly reduced disease activity in adults with active systemic lupus erythematosus (SLE) compared with placebo plus standard therapy, according to results from the phase 3 ALLEGORY trial published March 6 in the New England Journal of Medicine.^1,2 The data were simultaneously presented at the 15th European Lupus Meeting, SLEuro 2026.

The publication marks a significant step forward for a disease that has seen only a handful of approved therapies in the past 2 decades. Obinutuzumab is currently approved in the United States (US) and European Union for active lupus nephritis, but not for the broader SLE population — the indication studied in ALLEGORY.³

"The ALLEGORY study of Gazyva represents one of the most compelling late-stage successes in years for the treatment of patients with SLE, showing important evidence that targeting B cells can deliver significant reductions in disease activity,” Richard Furie, MD, Chief, Division of Rheumatology, Northwell Health, said in a statement.²

Trial Design

ALLEGORY (NCT04963296) was a phase 3, multicenter, double-blind, placebo-controlled trial enrolling 303 adults with active SLE but without proliferative or membranous lupus nephritis. Patients required a SLEDAI-2K score of 8 or higher at baseline, at least 1 BILAG domain A or 2 domain B scores, and seropositivity for ANA, anti-dsDNA, or anti-Smith antibodies with low complement levels. All were receiving stable standard therapy — antimalarials, nonglucocorticoid immunosuppressants, glucocorticoids, or a combination.

Patients were randomized 1:1 to intravenous obinutuzumab 1000 mg or placebo on day 1 and at weeks 2, 24, and 26. Disease activity and safety were assessed every 4 weeks through week 52. Stratification factors included screening SLEDAI-2K score (< 12 vs ≥ 12) and baseline prednisone dose (< 10 vs ≥ 10 mg/day).

The primary end point was SRI-4 response at week 52 — a composite requiring at least a 4-point reduction in SLEDAI-2K, no worsening of BILAG-2004 or Physician's Global Assessment scores, and no intercurrent events (major concomitant therapy violation, receipt of rescue medication, or early discontinuation). Five key secondary end points were assessed in a prespecified hierarchical sequence.

Primary End Point Results

At week 52, 76.7% of patients receiving obinutuzumab achieved SRI-4 response, compared with 53.5% of those receiving placebo (adjusted difference, 23.1 percentage points; 95% CI, 12.5–33.6; P <.001).¹

A post hoc supplementary analysis using a treatment policy strategy for all nonfatal intercurrent events yielded consistent results: SRI-4 response rates of 85.4% vs 68.5%, respectively (adjusted difference, 16.8 percentage points; 95% CI, 7.1–26.4; P <.001).¹

SLEDAI-2K scores declined over the treatment period, with between-group separation becoming apparent from weeks 24 through 52.¹

“With the ALLEGORY study, we are seeing the potential to deliver more robust and sustained disease control with less reliance on steroids. These benefits matter profoundly to patients, physicians and families, marking Gazyva as an important step forward in the treatment of this autoimmune disease,” Furie said.²

Key Secondary End Points

The prespecified hierarchical analysis demonstrated statistically significant between-group differences across all five key secondary end points:

• BICLA response at week 52: 62.0% vs 40.1% (adjusted difference, 21.9 pp; 95% CI, 10.8–32.9; P <.001)¹
• Sustained glucocorticoid reduction to ≤7.5 mg/day (weeks 40–52): 80.0% vs 54.1% among patients on ≥10 mg/day at baseline (adjusted difference, 30.2 pp; 95% CI, 15.3–45.1; P <.001)¹
• Sustained SRI-4 response (weeks 40–52): 72.0% vs 46.4% (adjusted difference, 25.4 pp; 95% CI, 14.6–36.2; P <.001)¹
• SRI-6 response at week 52: 68.9% vs 38.9% (adjusted difference, 30.0 pp; 95% CI, 19.2–40.7; P <.001)¹
• Median time to first BILAG-defined flare: Could not be estimated for obinutuzumab vs 52.3 weeks for placebo (HR, 0.58; 95% CI, 0.40–0.82; P =.002)¹

Among additional secondary end points not controlled for type I error, DORIS remission was achieved by 35.1% vs 13.8%, and LLDAS by 57.6% vs 25.0%, both at week 52.¹

Pharmacodynamics

Rapid and durable B-cell depletion was a defining pharmacodynamic feature. By week 2, 98.5% of patients in the obinutuzumab arm had complete peripheral CD19+ B-cell depletion, compared with 5.6% in the placebo arm. Depletion was maintained above 92% throughout the 52-week period. IgG levels remained within the normal range in both groups throughout the trial, a clinically relevant finding given the theoretical risk of immunoglobulin reduction with potent B-cell depleting agents.¹

Normalization of anti-dsDNA antibody titers and complement levels (C3, C4) was also more pronounced in the obinutuzumab group, consistent with the drug's mechanism of targeting a central upstream driver of SLE pathology.

Mechanism of Action

Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody. Its distinguishing features relative to type I agents — most notably rituximab — include enhanced FcγRIIIa binding, greater direct cell death, and increased antibody-dependent cellular cytotoxicity and phagocytosis, with reduced reliance on complement-dependent cytotoxicity.¹

The investigators noted that early trials of rituximab in SLE failed to confirm clinical benefit, with subsequent analyses suggesting that active SLE may require a greater degree of B-cell depletion than other autoimmune diseases such as rheumatoid arthritis. ALLEGORY's near-complete and sustained depletion profile appears to support this hypothesis, and the trial's results are consistent with emerging data from CAR-T therapies showing deep remissions in SLE tied to profound B-cell ablation.

Emerging biopsy data from the REGENCY lupus nephritis trial and a transplant desensitization study further indicate that obinutuzumab achieves B-cell depletion in tissue as well as peripherally — a potential mechanistic advantage that the ALLEGORY investigators acknowledge warrants further investigation in the SLE context.

Safety

The safety profile was consistent with the established profile of obinutuzumab. Adverse events occurred in 88.7% of patients in the obinutuzumab group and 81.5% in the placebo group; grade ≥3 adverse events were reported in 16.6% and 13.9%, respectively. Serious adverse events occurred in 15.9% vs 11.9%.¹

The most common serious adverse events with obinutuzumab were pneumonia (2.0%), and upper respiratory tract infection, urinary tract infection, and infusion-related reactions (1.3% each). Infusion-related reactions occurred more frequently with obinutuzumab than placebo (11.9% vs 3.3%) and were predominantly grade 1 or 2, concentrated at the first infusion.¹

Drug-related neutropenia events occurred in 7 patients (8 events total) in the obinutuzumab arm and 3 patients in the placebo arm; all resolved within a mean of 35 days. One patient with grade 3 neutropenia received filgrastim. COVID-19 was reported in 9 (6.0%) obinutuzumab patients and 6 (4.0%) placebo patients, with all cases resolving in the outpatient setting.¹

Four deaths occurred during the double-blind period: 1 in the obinutuzumab group (soft-tissue infection and pneumonia) and 3 in the placebo group (pulmonary alveolar hemorrhage, myocarditis with sepsis, and an SLE flare). No new or unexpected safety signals were identified.

Clinical Context and Regulatory Status

SLE affects more than 3 million people worldwide, predominantly women between the ages of 15 and 45, with a disproportionate burden among women of color. Frequent flares drive cumulative, irreversible organ damage, and approximately half of patients progress to lupus nephritis within 5 years of diagnosis.

Obinutuzumab was previously approved by the US Food and Drug Administration (FDA) in October 2025 for adults with active lupus nephritis, based on data from the REGENCY and NOBILITY studies.² ALLEGORY represents a different and broader indication — active SLE without renal involvement meeting the proteinuria exclusion threshold. Roche has stated it is discussing ALLEGORY data with health authorities, including the FDA and EMA, with the goal of seeking approval in SLE.

ALLEGORY joins REGENCY (lupus nephritis), INShore (idiopathic nephrotic syndrome), and MAJESTY (primary membranous nephropathy) as the fourth positive phase 3 study for obinutuzumab in immune-mediated diseases — a growing evidence base that reinforces B-cell depletion as a transdiagnostic therapeutic target.¹

Study Limitations

The investigators noted several limitations. Patients with severely active lupus nephritis or central nervous system SLE were excluded, limiting generalizability to those populations — though REGENCY has separately established obinutuzumab's efficacy in the nephritis setting. The 52-week primary analysis window precludes conclusions about long-term durability. Additionally, because no tissue sampling was performed in ALLEGORY, the contribution of tissue-level B-cell depletion to the observed clinical responses cannot be directly assessed.

“For decades, people living with SLE have faced a cycle of unpredictable disease activity, limited treatment options and long-term steroid burden. These results from the ALLEGORY trial show that Gazyva/Gazyvaro can provide significant, clinically meaningful, and sustained disease control, which is critical to preventing life threatening damage to major organs,” Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development, added.² “We look forward to working with health authorities around the world to bring this potentially transformative new treatment to patients with lupus as quickly as possible. ”

References

1. Furie R, et al. Obinutuzumab for Systemic Lupus Erythematosus. N Engl J Med. Published March 6, 2026. doi:10.1056/NEJMoa2413847

2. New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus. News release. Roche. March 5, 2026. https://www.roche.com/media/releases/med-cor-2026-03-06

3. Brooks A. FDA Approves Obinutuzumab (Gazyva) for Lupus Nephritis. Article. Rheumatology Live. October 20, 2025. https://www.rheum-live.com/view/fda-approves-obinutuzumab-gazyva-for-lupus-nephritis